跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 12 天前AI 评分14

Biodexa Pharmaceuticals PLC 提交 6-K 文件并附上新闻稿

6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

AI 导读

Biodexa Pharmaceuticals PLC 提交了 2026 年 11 月的 6-K 文件,随附一份日期为 11 月 9 日的新闻稿。文件称,该新闻稿作为附件提供,不视为依据《1934 年证券交易法》第 18 条提交。

正文

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-37652

Biodexa Pharmaceuticals PLC
(Translation of registrant's name into English)

1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.


SUBMITTED HEREWITH:

Exhibit Number Description
   
99.1 Press Release dated November 9, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Biodexa Pharmaceuticals PLC    
  (Registrant)
   
  
Date: November 9, 2026     /s/ Stephen Stamp    
  Stephen Stamp
  Chief Executive Officer, Chief Financial Officer
  

来源:SEC EDGAR · 本站存档